Comparative Study Between Alzheimer's and Multi-infarct Dementia

Comparative Study Between Alzheimer's and Multi-infarct Dementia Regarding to Clinical Aspect, Biomarker, and Cortical Excitability

Dementia is a neurological disease that causes cognitive and behavioral impairments that could ultimately interfere with the ability to function at work or to do the usual daily activities. It is recognized as a healthcare and social burden and remains challenging in terms of proper diagnosis and treatment.

Study Overview

• Status: Recruiting
• Conditions: Dementia
• Intervention / Treatment: Diagnostic test: levels of Neurofilaments (NfL) in serum

Detailed Description

Biomarkers are needed to identify at-risk individuals, stage their disease, and track disease progression. Such biomarkers should be noninvasive, inexpensive, and simple to acquire. Neurodegeneration biomarkers in CSF include neurofilament light (NfL), Chitinase 3-like protein 1 (CHI3L1). NfL for example increases in several neurologic conditions, including AD. In addition, NfL can be detected in serum using standard immunoassay formats. Higher CSF levels of CHI3L1 are seen in patients with neurological disorders such as MS patients experiencing relapses of MS. In addition, C-X-C motif chemokine 13 (CXCL13) is a crucial homeostatic chemokine expressed in lymphoid organs, and it is essential for the recruitment and compartmentalization of lymphocytes. In MS, CXCL13 regulates homing of B cells and subsets of T cells to inflammatory foci in CNS by interacting with the CXCR5 receptor. The levels of CXCL13 are elevated in the CSF of patients with MS compared to healthy controls, as well as in other neuroinflammatory diseases. CXCL13 may be considered a CSF biomarker of intrathecal B cell response, as its levels correlate with the count of B cells, the IgG index, and the presence and OCBs in the CSF.

Transcranial magnetic stimulation (TMS) assesses several cortical properties such as excitability, plasticity, and connectivity in humans. TMS has been applied to patients with dementia, enabling the identification of potential markers of the pathophysiology and predictors of cognitive decline; moreover, applied repetitively, TMS holds promise as a potential therapeutic intervention.

• Study Type: Observational
• Enrollment (Anticipated): 76

Contacts and Locations

• Study Contact: Name: Esraa A Abdelregal, ass lecturer; Phone Number: 00201033400846; Email: esraa161292@gmail.com
• Study Contact Backup: Name: Noha M Aboelfetoh, professor; Phone Number: 01006800910; Email: nohaaboelfetoh@aun.edu.eg

Study Locations

• Egypt
  • Assiut, Egypt
    • Recruiting
    • Medicine
    • Contact: Esraa A Abdelregal, ass lecturer; Phone Number: 00201033400846; Email: esraa161292@gmail.com
    • Contact: Noha M Aboelfotoh, Professor; Phone Number: 00201006800910; Email: nohaaboelfetoh@aun.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

case control study, it will include 4 groups of dementia patients in early and late onset, and control healthy group matching with age, sex and educational state.

The study will include 19 patient of each dementia type and 19 controls, each dementia patients were diagnosed according to the international classification of disease 10th revision ICD 10.

Total score of Mini-mental state examination is <24 or 22 in Mini-mental state examination will be used as a screening test for detection of cases.

Description

Inclusion Criteria:

1. Men or women of at least 50-80 years of age.
2. Are reliable in individual data and willing to make themselves available for the duration of the study
3. Clear written informed consent obtained from 1st degree of relative from each patient participant and control himself in the trial.

Exclusion Criteria:

1. age below 50 years and above 80 years.
2. other neurological disorders or psychiatric disorders; previous history of stroke; metabolic disturbance; other major medical illnesses; epilepsy; inflammatory, autoimmune, or infectious disease; metallic objects in the body; craniotomy in the past.
3. Presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study
4. Participation in any other type of medical research that may interfere with the interpretation of the study.
5. Patients with severe motor disability (bed-ridden) that may interfere with the study procedure.
6. Patients with history of seizures or epilepsy including history in a first degree relative

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Early onset Alzhiemer; before age of 65 and above age of 50	Diagnostic test: levels of Neurofilaments (NfL) in serum; the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
Late onset Alzhiemer; Above the age of 65	Diagnostic test: levels of Neurofilaments (NfL) in serum; the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
Vascular dementia; Any patient diagnosed with vascular dementia	Diagnostic test: levels of Neurofilaments (NfL) in serum; the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
control group; persons who has no dementia	Diagnostic test: levels of Neurofilaments (NfL) in serum; the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
detect difference between multiple types of dementia (Alzheimer's disease with early onset, and late-onset as well as multi-infarct dementia )	detect difference between multiple types of dementia (Alzheimer's disease with early onset, and late-onset as well as multi-infarct dementia ) regarding clinical profile, biomarkers, and cortical excitability	2 years

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Study Chair: Eman M Khedr, professor, Assiut University

Publications and helpful links

General Publications

• Antczak J, Rusin G, Slowik A. Transcranial Magnetic Stimulation as a Diagnostic and Therapeutic Tool in Various Types of Dementia. J Clin Med. 2021 Jun 28;10(13):2875. doi: 10.3390/jcm10132875.
• Elshahidi MH, Elhadidi MA, Sharaqi AA, Mostafa A, Elzhery MA. Prevalence of dementia in Egypt: a systematic review. Neuropsychiatr Dis Treat. 2017 Mar 6;13:715-720. doi: 10.2147/NDT.S127605. eCollection 2017.
• Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, Druyeh R, Malone IB, Ahsan RL, Pemberton H, Klimova J, Mead S, Blennow K, Rossor MN, Schott JM, Zetterberg H, Fox NC. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017 Nov 21;89(21):2167-2175. doi: 10.1212/WNL.0000000000004667. Epub 2017 Oct 25.

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2023
• Primary Completion (Anticipated): July 21, 2025
• Study Completion (Anticipated): February 21, 2026

Study Registration Dates

• First Submitted: February 20, 2023
• First Submitted That Met QC Criteria: March 11, 2023
• First Posted (Actual): March 23, 2023

Study Record Updates

• Last Update Posted (Actual): March 23, 2023
• Last Update Submitted That Met QC Criteria: March 11, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Ischemia; Pathologic Processes; Necrosis; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Genetic Diseases, Inborn; Brain Ischemia; Infarction; Stroke; Brain Infarction; Cerebral Arterial Diseases; Intracranial Arterial Diseases; Cerebral Small Vessel Diseases; Cerebral Infarction; Dementia, Vascular; Dementia; CADASIL; Dementia, Multi-Infarct
• Other Study ID Numbers: Dementia

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO